Antineoplastic CAS 1038915-60-4 Niraparib Powder Purity Niraparib Powder Pharmaceuticals Niraparib

China Antineoplastic CAS 1038915-60-4 Niraparib Powder Purity Niraparib Powder Pharmaceuticals Niraparib, Find details about China Niraparib, Niraparib Powder from Antineoplastic CAS 1038915-60-4 Niraparib Powder Purity Niraparib Powder Pharmaceuticals Niraparib

Model NO.
D-Sung Niraparib
Product Name
Niraparib
Name
Niraparib Powder
Appearance
White Powder
Color
White
Store
Cool and Dry
Grade
Pharmaceutical Grade
Assay
HPLC 99%
Application
Anthelmintics
Specific
COA
Test Method
HPLC
Shelf Life
2 Years
CAS No.
1038915-60-4
Mf
C19h20n4o
Boiling Point
463.619 C at 760 Mmhg
Density
1.343
Trademark
D-Sung
Transport Package
Negotiable
Specification
99%
Origin
Xi′an Shaanxi
Model NO.
D-Sung Niraparib
Product Name
Niraparib
Name
Niraparib Powder
Appearance
White Powder
Color
White
Store
Cool and Dry
Grade
Pharmaceutical Grade
Assay
HPLC 99%
Application
Anthelmintics
Specific
COA
Test Method
HPLC
Shelf Life
2 Years
CAS No.
1038915-60-4
Mf
C19h20n4o
Boiling Point
463.619 C at 760 Mmhg
Density
1.343
Trademark
D-Sung
Transport Package
Negotiable
Specification
99%
Origin
Xi′an Shaanxi
Antineoplastic CAS 1038915-60-4 Niraparib Powder Purity Niraparib Powder Pharmaceuticals Niraparib
Antineoplastic CAS 1038915-60-4 Niraparib Powder Purity Niraparib Powder Pharmaceuticals Niraparib
Product Description

Antineoplastic CAS 1038915-60-4 Niraparib Powder Purity Niraparib Powder Pharmaceuticals NiraparibAntineoplastic CAS 1038915-60-4 Niraparib Powder Purity Niraparib Powder Pharmaceuticals Niraparib

Product Details

Antineoplastic CAS 1038915-60-4 Niraparib Powder Purity Niraparib Powder Pharmaceuticals Niraparib

Product NameNiraparib
AppearanceWhite Powder
CAS No.1038915-60-4
MFC19H20N4O
Niraparib is an orally active small molecule PARP inhibitor developed by Tesaro to treat ovarian cancer.
Application&Function

Antineoplastic CAS 1038915-60-4 Niraparib Powder Purity Niraparib Powder Pharmaceuticals NiraparibNiraparib  is an orally active small molecule PARP inhibitor developed by Tesaro to treat ovarian cancer..
The drug is approved by the US FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

Specification

Antineoplastic CAS 1038915-60-4 Niraparib Powder Purity Niraparib Powder Pharmaceuticals NiraparibAntineoplastic CAS 1038915-60-4 Niraparib Powder Purity Niraparib Powder Pharmaceuticals NiraparibAntineoplastic CAS 1038915-60-4 Niraparib Powder Purity Niraparib Powder Pharmaceuticals NiraparibAntineoplastic CAS 1038915-60-4 Niraparib Powder Purity Niraparib Powder Pharmaceuticals NiraparibAntineoplastic CAS 1038915-60-4 Niraparib Powder Purity Niraparib Powder Pharmaceuticals NiraparibAntineoplastic CAS 1038915-60-4 Niraparib Powder Purity Niraparib Powder Pharmaceuticals NiraparibAntineoplastic CAS 1038915-60-4 Niraparib Powder Purity Niraparib Powder Pharmaceuticals Niraparib